Interview: Summit Hits The Heights With Billionaire Backing
Ex-Pharmacyclics CEO Bob Duggan is to invest $25m into Summit Therapeutics, taking a near 49% stake in the UK firm and helping it fund Phase III trials for the Oxford-based firm's lead antibiotic candidate ridinilazole.
You may also be interested in...
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.